426 related articles for article (PubMed ID: 33907692)
1. TNFR2: Role in Cancer Immunology and Immunotherapy.
Yang Y; Islam MS; Hu Y; Chen X
Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
[TBL] [Abstract][Full Text] [Related]
2. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis.
Ye LL; Peng WB; Niu YR; Xiang X; Wei XS; Wang ZH; Wang X; Zhang SY; Chen X; Zhou Q
Ann Transl Med; 2020 Dec; 8(24):1647. PubMed ID: 33490159
[TBL] [Abstract][Full Text] [Related]
4. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract][Full Text] [Related]
5. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
Zou H; Li R; Hu H; Hu Y; Chen X
Front Immunol; 2018; 9():594. PubMed ID: 29632537
[TBL] [Abstract][Full Text] [Related]
7. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
8. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4
Islam MS; Yang Y; Chen X
Adv Exp Med Biol; 2021; 1278():257-272. PubMed ID: 33523452
[TBL] [Abstract][Full Text] [Related]
9. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
10. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
[TBL] [Abstract][Full Text] [Related]
11. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
12. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
13. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
[TBL] [Abstract][Full Text] [Related]
14. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells.
Kampan NC; Madondo MT; McNally OM; Stephens AN; Quinn MA; Plebanski M
Front Immunol; 2017; 8():1482. PubMed ID: 29163543
[TBL] [Abstract][Full Text] [Related]
16. TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and
Shaikh F; He J; Bhadra P; Chen X; Siu SWI
Front Immunol; 2018; 9():1382. PubMed ID: 29967617
[TBL] [Abstract][Full Text] [Related]
17. Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.
Li M; Zhang X; Bai X; Liang T
Front Oncol; 2022; 12():862154. PubMed ID: 35494080
[TBL] [Abstract][Full Text] [Related]
18. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
19. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
